Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). (Q40352514)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 November 2015

Language	Label	Description	Also known as
English	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).	scientific article published on 5 November 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Francesco Leone

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Donatella Marino

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Guglielmo Nasti

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Celeste Cagnazzo

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Salvatore Siena

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Massimo Aglietta

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Stefano Cereda

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Rosella Spadi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Massimo Montano

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Giuseppe Aprile

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Gianpiero Fasola

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Libero Ciuffreda

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Michele Reni

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

0 references

publication date

5 November 2015

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

122

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

574-581

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Prognostic factors in patients with gallbladder cancer after surgical resection: analysis of 279 operated patients

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Biliary tract carcinomas: from chemotherapy to targeted therapy.

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

21 January 2018

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study

1 reference

https://api.crossref.org/works/10.1002/CNCR.29778

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.29778

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26540314 AND SRC:MED&resulttype=core&format=json

6 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40352514&oldid=2138134426"